Study on Therapeutic Drug Monitoring of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus and Its Efficacy.

Negita, Kazumasa; Yamashita, Masayo; Kubota, T; Sugiura, Youji; Miura, Takanori; Katsumi, Akio; M, Ohta; Saitake, Tatsuro; Tozawa, Y.; Mizutani, Masaru

doi:10.5649/jjphcs.27.123

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The renal-related adverse drug reactions of arbekacin are increased with a higher Ctrough [11]. The incidence of arbekacin induced nephrotoxicity was observed when it was administrated at a total dose of over 5000 mg [20]. Moreover, with a dose spacing of 72 h, the Ctrough will be lower.…”

Section: Sarkar Et Almentioning

confidence: 99%

Arbekacin – A Ray of Hope to Fight Against MDR and XDR Gram-Negative Bacteria in a Scientific and Cost-Effective Way in Indian Scenario

Sarkar

SARKAR

NAMHATA

et al. 2020

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: The objective of the study was to see the in vitro activity of arbekacin, a novel aminoglycoside, against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacilli (GNB) so that it can become a good alternative as empirical treatment for severe sepsis. Methods: Identification and antibiotic sensitivity testing of the GNB isolated from the clinical samples were done using the VITEK-II system in a tertiary care hospital, Kolkata. MDR and XDR strains were selected by their definitions and molecular characterization was done by multiplex polymerase chain reaction. The minimum inhibitory concentration (MIC) value of arbekacin was detected by the E-test strip and compared with other aminoglycosides. Results: A total of 140 drug-resistant strains including ESBL- and carbapenemase-producing GNB were selected for the study. Arbekacin showed reduced values of MIC50 and MIC90 compared to other aminoglycosides for most of the drug-resistant GNB. Conclusion: Hence, in this drug-resistant era, arbekacin with the advantage of a single daily dose can be used as an empirical choice in severe sepsis as monotherapy or in combination with other antibiotics such as colistin or polymyxin to fight against MDR and XDR bugs.

show abstract

Section: Sarkar Et Almentioning

confidence: 99%

Arbekacin – A Ray of Hope to Fight Against MDR and XDR Gram-Negative Bacteria in a Scientific and Cost-Effective Way in Indian Scenario

Sarkar

SARKAR

NAMHATA

et al. 2020

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…When Ctrough was 1, 2 or 5 μg/mL, the estimated rate of adverse drug reactions were 2.5, 5.2, and 13.1% respectively, and the incidence of renal-related adverse drug reactions increased with a higher C trough . 44 trough The incidence of ABK-induced nephrotoxicity was observed in all patients when ABK was administrated at a total dose of over 5,000 mg, while it was 4% at a total dose of less than 5,000 mg. 45 …”

Section: Adverse Effect Of Abkmentioning

confidence: 99%

Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens

Matsumoto¹

2014

CPAA

View full text Add to dashboard Cite

Arbekacin sulfate (ABK), an aminoglycoside antibiotic, was discovered in 1972 and was derived from dibekacin to stabilize many common aminoglycoside modifying enzymes. ABK shows broad antimicrobial activities against not only Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) but also Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. ABK has been approved as an injectable formulation in Japan since 1990, under the trade name Habekacin, for the treatment of patients with pneumonia and sepsis caused by MRSA. The drug has been used in more than 250,000 patients, and its clinical benefit and safety have been proven over two decades. ABK currently shows promise for the application for the treatment of multidrug-resistant Gram-negative bacterial infections such as multidrug-resistant strains of P. aeruginosa and Acinetobacter baumannii because of its synergistic effect in combination with beta-lactams.

show abstract

“…A number of studies have shown that it has dose‐dependent bactericidal action with a significant post‐antibiotic effect. The side‐effects include nephrotoxicity and ototoxicity (10–16). However, arbekacin is principally eliminated by renal excretion, and the initial dose is normally determined using the population mean method based on the estimated GFR using the serum creatinine concentration.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the clinical application of cystatin C, a new marker of the glomerular filtration rate, for the initial dose-setting of arbekacin

et al. 2008

View full text Add to dashboard Cite

show abstract

Study on Therapeutic Drug Monitoring of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus and Its Efficacy.

Cited by 4 publications

References 0 publications

Arbekacin – A Ray of Hope to Fight Against MDR and XDR Gram-Negative Bacteria in a Scientific and Cost-Effective Way in Indian Scenario

Arbekacin – A Ray of Hope to Fight Against MDR and XDR Gram-Negative Bacteria in a Scientific and Cost-Effective Way in Indian Scenario

Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens

Evaluation of the clinical application of cystatin C, a new marker of the glomerular filtration rate, for the initial dose-setting of arbekacin

Contact Info

Product

Resources

About